Title:
ANTICANCER FUSION PROTEIN
Document Type and Number:
WIPO Patent Application WO/2012/143477
Kind Code:
A3
Abstract:
A fusion protein comprising domain (a) which is the functional fragment of a hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and at least one domain (b) which is the sequence of an effector peptide having anti-proliferative activity against tumour cells, wherein the sequence of domain (b) is attached at the C-terminus or at the N-terminus of domain (a).The fusion protein can be used for the treatment of cancer diseases.
Inventors:
PIECZYKOLAN JERZY SZCZEPAN (PL)
PAWLAK SEBASTIAN DOMINIK (PL)
ZEREK BARTLOMIEJ MACIEJ (PL)
ROZGA PIOTR KAMIL (PL)
SZAWLOWSKA URSZULA MARTA (PL)
PAWLAK SEBASTIAN DOMINIK (PL)
ZEREK BARTLOMIEJ MACIEJ (PL)
ROZGA PIOTR KAMIL (PL)
SZAWLOWSKA URSZULA MARTA (PL)
Application Number:
PCT/EP2012/057219
Publication Date:
March 14, 2013
Filing Date:
April 19, 2012
Export Citation:
Assignee:
ADAMED SP ZOO (PL)
PIECZYKOLAN JERZY SZCZEPAN (PL)
PAWLAK SEBASTIAN DOMINIK (PL)
ZEREK BARTLOMIEJ MACIEJ (PL)
ROZGA PIOTR KAMIL (PL)
SZAWLOWSKA URSZULA MARTA (PL)
PIECZYKOLAN JERZY SZCZEPAN (PL)
PAWLAK SEBASTIAN DOMINIK (PL)
ZEREK BARTLOMIEJ MACIEJ (PL)
ROZGA PIOTR KAMIL (PL)
SZAWLOWSKA URSZULA MARTA (PL)
International Classes:
C07K14/705; C12N15/12; C12N15/62; A61K38/17; A61P35/00
Domestic Patent References:
| WO2009025846A2 | 2009-02-26 | |||
| WO2002020715A2 | 2002-03-14 | |||
| WO2011161260A1 | 2011-12-29 |
Other References:
SHIN J N ET AL: "Generation of a novel proform of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein that can be reactivated by matrix metalloproteinases", EXPERIMENTAL CELL RESEARCH, ACADEMIC PRESS, US, vol. 312, no. 19, 15 November 2006 (2006-11-15), pages 3892 - 3898, XP024945270, ISSN: 0014-4827, [retrieved on 20061115], DOI: 10.1016/J.YEXCR.2006.08.015
MIN YOU ET AL: "The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 394, no. 3, 1 April 2010 (2010-04-01), pages 760 - 766, XP055049337, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2010.03.066
C. WANG ET AL: "Melittin, a Major Component of Bee Venom, Sensitizes Human Hepatocellular Carcinoma Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Activating CaMKII-TAK1-JNK/p38 and Inhibiting I B Kinase-NF B", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, no. 6, 1 January 2008 (2008-01-01), pages 3804 - 3813, XP055049376, ISSN: 0021-9258, DOI: 10.1074/jbc.M807191200
K FUJIMOTO: "Inhibition of pRb phosphorylation and cell cycle progression by an antennapedia-p16INK4A fusion peptide in pancreatic cancer cells", CANCER LETTERS, vol. 159, no. 2, 31 October 2000 (2000-10-31), pages 151 - 158, XP055049353, ISSN: 0304-3835, DOI: 10.1016/S0304-3835(00)00536-X
KATSUHIKO KONO: "In vitro growth suppression of human glioma cells by a 16-mer oligopeptide: a potential new treatment modality for malignant glioma", JOURNAL OF NEURO-ONCOLOGY, vol. 63, no. 2, 1 January 2003 (2003-01-01), pages 163 - 171, XP055049261, ISSN: 0167-594X, DOI: 10.1023/A:1023908307863
GERALD J. MIZEJEWSKI: "The Alpha-Fetoprotein-Derived Growth Inhibitory Peptide 8-Mer Fragment: Review of a Novel Anticancer Agent", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 22, no. 1, 1 February 2007 (2007-02-01), pages 73 - 98, XP055049469, ISSN: 1084-9785, DOI: 10.1089/cbr.2006.343
JEANNETTE GERSPACH ET AL: "Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 55, no. 12, 25 April 2006 (2006-04-25), pages 1590 - 1600, XP019422516, ISSN: 1432-0851, DOI: 10.1007/S00262-006-0162-6
MÉRINO DELPHINE ET AL: "TRAIL in cancer therapy: present and future challenges", EXPERT OPINION ON THERAPEUTIC TARGETS,, vol. 11, no. 10, 1 October 2007 (2007-10-01), pages 1299 - 1314, XP008148995, ISSN: 1744-7631, DOI: 10.1517/14728222.11.10.1299
MIN YOU ET AL: "The combination of ADI-PEG20 and TRAIL effectively increases cell death in melanoma cell lines", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 394, no. 3, 1 April 2010 (2010-04-01), pages 760 - 766, XP055049337, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2010.03.066
C. WANG ET AL: "Melittin, a Major Component of Bee Venom, Sensitizes Human Hepatocellular Carcinoma Cells to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-induced Apoptosis by Activating CaMKII-TAK1-JNK/p38 and Inhibiting I B Kinase-NF B", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, no. 6, 1 January 2008 (2008-01-01), pages 3804 - 3813, XP055049376, ISSN: 0021-9258, DOI: 10.1074/jbc.M807191200
K FUJIMOTO: "Inhibition of pRb phosphorylation and cell cycle progression by an antennapedia-p16INK4A fusion peptide in pancreatic cancer cells", CANCER LETTERS, vol. 159, no. 2, 31 October 2000 (2000-10-31), pages 151 - 158, XP055049353, ISSN: 0304-3835, DOI: 10.1016/S0304-3835(00)00536-X
KATSUHIKO KONO: "In vitro growth suppression of human glioma cells by a 16-mer oligopeptide: a potential new treatment modality for malignant glioma", JOURNAL OF NEURO-ONCOLOGY, vol. 63, no. 2, 1 January 2003 (2003-01-01), pages 163 - 171, XP055049261, ISSN: 0167-594X, DOI: 10.1023/A:1023908307863
GERALD J. MIZEJEWSKI: "The Alpha-Fetoprotein-Derived Growth Inhibitory Peptide 8-Mer Fragment: Review of a Novel Anticancer Agent", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 22, no. 1, 1 February 2007 (2007-02-01), pages 73 - 98, XP055049469, ISSN: 1084-9785, DOI: 10.1089/cbr.2006.343
JEANNETTE GERSPACH ET AL: "Target-selective activation of a TNF prodrug by urokinase-type plasminogen activator (uPA) mediated proteolytic processing at the cell surface", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 55, no. 12, 25 April 2006 (2006-04-25), pages 1590 - 1600, XP019422516, ISSN: 1432-0851, DOI: 10.1007/S00262-006-0162-6
MÉRINO DELPHINE ET AL: "TRAIL in cancer therapy: present and future challenges", EXPERT OPINION ON THERAPEUTIC TARGETS,, vol. 11, no. 10, 1 October 2007 (2007-10-01), pages 1299 - 1314, XP008148995, ISSN: 1744-7631, DOI: 10.1517/14728222.11.10.1299
Attorney, Agent or Firm:
SITKOWSKA, Jadwiga (Warszawa, PL)
Download PDF:
Previous Patent: BLACKOUT DEVICE PROVIDING IMPROVED CONVENIENCE OF USE
Next Patent: DEVICE AND METHOD FOR PLUGGING A HOLE IN A MEMBRANE
Next Patent: DEVICE AND METHOD FOR PLUGGING A HOLE IN A MEMBRANE